mammalian manufacturing
mammalian manufacturing
Lonza Launches First GMP Batch at New Facility!
🌟 Lonza's first GMP batch at its new Portsmouth facility marks a leap in biomanufacturing, supporting innovative therapies! 💊🚀🔧
Lonza Boosts US Manufacturing with $12B Acquisition!
🚀 Lonza has acquired Roche's Vacaville site for $1.2 billion, boosting U.S. manufacturing and investing $591 million for upgrades! 🏭✨
Revolutionary Kyverna Cuts CAR-T Production to 3 Days
📰 CAR-T, a gamechanger in cancer treatment, could revolutionize patient access and save lives with Kyverna's 3-day process. 💉🔬
Boosting Manufacturing Efficiency: AI’s Role in Cutting Costs and Enhancing Therapies
🧪 AI accelerates commercialization strategies by cutting costs and improving processes in advanced therapy manufacturing. 🔬 5 of batches fail, impacting health and revenues. 🧠 AI is crucial for complex therapies. 💰 Manufacturers need to optimize processes and reduce costs. 🌐 AI enables learning transfer and supports decision-making. 📈 Industry 4.0 will use machine learning for real-time predictions and support.
Lonza shuts down Swiss manufacturing site cutting 190 jobs
📢 Lonza is decommissioning its mammalian manufacturing site in Visp, Switzerland, after 30 years of operation. 🏭✅ This decision is driven by market dynamics and the need for flexibility. ❌ However, Lonza will focus on other sites and genecell therapies. 😔 Around 190 jobs will be lost.
